Log In
Print
BCIQ
Print
Print this Print this
 

Vitekta, elvitegravir (GS 9137)

Also known as: JTK-303

  Manage Alerts
Collapse Summary General Information
Company Japan Tobacco Inc.
DescriptionHIV integrase inhibitor
Molecular Target HIV integrase
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentMarketed
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV-1 infection; Treat HIV-1 infection in adults without known mutations associated with resistance to elvitegravir
Regulatory Designation

U.S. - Undisclosed Review (Treat HIV-1 infection);
EU - Standard Review (Treat HIV-1 infection);
Japan - Orphan Drug (Treat HIV-1 infection)

Partner

Gilead Sciences Inc.; Torii Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today